Literature DB >> 29931387

[Treatment of chronic pruritus-what is new?]

C Zeidler1, M Metz2, S Steinke3, S Ständer3.   

Abstract

Chronic pruritus is one of the most common and stressful symptoms in medicine. Therapy remains a great challenge because of the lack of approved therapies. In the recent past a greater understanding of the pathogenesis has enabled the results to be translated into new forms of therapy. The various therapies target a wide range of points in the pruritic cascade-from blockade of intracellular and intercellular signaling pathways in the skin to the modulation of neurotransmission. This article provides a summary of current therapeutic options based on the current S2K guideline and gives an overview about recent developments in antipruritic treatments.

Entities:  

Keywords:  Biologics; Itch; Neurotransmission; Quality of life; Signal pathways

Mesh:

Substances:

Year:  2018        PMID: 29931387     DOI: 10.1007/s00105-018-4221-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  37 in total

1.  Correlation of IL-31 serum levels with severity of atopic dermatitis.

Authors:  Ulrike Raap; Katja Wichmann; Manuela Bruder; Sonja Ständer; Bettina Wedi; Alexander Kapp; Thomas Werfel
Journal:  J Allergy Clin Immunol       Date:  2008-08       Impact factor: 10.793

2.  A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Authors:  Kenneth B Gordon; Kristina Callis Duffin; Robert Bissonnette; Jörg C Prinz; Yasmine Wasfi; Shu Li; Yaung-Kaung Shen; Philippe Szapary; Bruce Randazzo; Kristian Reich
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

3.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Authors:  Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert
Journal:  J Am Acad Dermatol       Date:  2016-07-11       Impact factor: 11.527

4.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Authors:  Kenneth B Gordon; Jean-Frederic Colombel; Dana S Hardin
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

5.  The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Edith M M Kuiper; Karel J van Erpecum; Ulrich Beuers; Bettina E Hansen; H Bing Thio; Robert A de Man; Harry L A Janssen; Henk R van Buuren
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 6.  Targeting Itch with Ligands Selective for κ Opioid Receptors.

Authors:  Alan Cowan; George B Kehner; Saadet Inan
Journal:  Handb Exp Pharmacol       Date:  2015

7.  Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.

Authors:  Steven R Feldman; Diamant Thaçi; Melinda Gooderham; Matthias Augustin; Claudia de la Cruz; Lotus Mallbris; Marjorie Buonanno; Svitlana Tatulych; Mandeep Kaur; Shuping Lan; Hernan Valdez; Carla Mamolo
Journal:  J Am Acad Dermatol       Date:  2016-09-28       Impact factor: 11.527

8.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

9.  Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

Authors:  R Bissonnette; K A Papp; Y Poulin; M Gooderham; M Raman; L Mallbris; C Wang; V Purohit; C Mamolo; J Papacharalambous; W C Ports
Journal:  Br J Dermatol       Date:  2016-09-24       Impact factor: 9.302

10.  Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Authors:  K A Papp; A Blauvelt; A B Kimball; C Han; B Randazzo; Y Wasfi; Y-K Shen; S Li; C E M Griffiths
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-04-10       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.